BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Salas A, Hernandez-Rocha C, Duijvestein M, Faubion W, McGovern D, Vermeire S, Vetrano S, Vande Casteele N. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2020;17:323-37. [PMID: 32203403 DOI: 10.1038/s41575-020-0273-0] [Cited by in Crossref: 141] [Cited by in F6Publishing: 148] [Article Influence: 70.5] [Reference Citation Analysis]
Number Citing Articles
1 Wu H, Ke X, Huang W, Shi W, Yao S, Duan YY, Tian W, Dong SS, Xue HZ, Guo Y. Multi-Tissue Integrative Analysis Identifies Susceptibility Genes for Atopic Dermatitis. J Invest Dermatol 2022:S0022-202X(22)01940-6. [PMID: 36155055 DOI: 10.1016/j.jid.2022.09.006] [Reference Citation Analysis]
2 Liu G, Kamilijiang M, Abuduwaili A, Zang D, Abudukelimu N, Liu G, Yili A, AIsa HA. Isolation, structure elucidation, and biological activity of polysaccharides from Saussurea involucrata. Int J Biol Macromol 2022;222:154-66. [PMID: 36122780 DOI: 10.1016/j.ijbiomac.2022.09.137] [Reference Citation Analysis]
3 Vieujean S, D’amico F, Netter P, Danese S, Peyrin‐biroulet L. Landscape of new drugs and targets in inflammatory bowel disease. UEG Journal. [DOI: 10.1002/ueg2.12305] [Reference Citation Analysis]
4 Vuyyuru SK, Kedia S, Ahuja V. Considerations when starting patients on multiple biologics and small molecules. Curr Opin Gastroenterol 2022. [PMID: 36165042 DOI: 10.1097/MOG.0000000000000886] [Reference Citation Analysis]
5 Zhang HY, Zeng HR, Wei HZ, Chu XY, Zhu HT, Zhao B, Zhang Y. Tongxie-Yaofang formula regulated macrophage polarization to ameliorate DSS-induced colitis via NF-κB/NLRP3 signaling pathway. Phytomedicine 2022;107:154455. [PMID: 36182797 DOI: 10.1016/j.phymed.2022.154455] [Reference Citation Analysis]
6 Hartel JC, Merz N, Grösch S. How sphingolipids affect T cells in the resolution of inflammation. Front Pharmacol 2022;13:1002915. [DOI: 10.3389/fphar.2022.1002915] [Reference Citation Analysis]
7 Elfiky AMI, Hageman IL, Becker MAJ, Verhoeff J, Li Yim AYF, Joustra VW, Mulders L, Fung I, Rioja I, Prinjha RK, Smithers NN, Furze RC, Mander PK, Bell MJ, Buskens CJ, D’haens GR, Wildenberg ME, de Jonge WJ. A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn’s Disease. Cells 2022;11:2846. [DOI: 10.3390/cells11182846] [Reference Citation Analysis]
8 Sanachai K, Mahalapbutr P, Hengphasatporn K, Shigeta Y, Seetaha S, Tabtimmai L, Langer T, Wolschann P, Kittikool T, Yotphan S, Choowongkomon K, Rungrotmongkol T. Pharmacophore-Based Virtual Screening and Experimental Validation of Pyrazolone-Derived Inhibitors toward Janus Kinases. ACS Omega. [DOI: 10.1021/acsomega.2c04535] [Reference Citation Analysis]
9 Liang X, Xie Y, Liu X, Xu H, Ren H, Tang S, Liu Q, Huang M, Shao X, Li C, Zhou Y, Geng M, Xie Z, Liu H. Discovery of Novel Imidazo[4,5-c]quinoline Derivatives to Treat Inflammatory Bowel Disease (IBD) by Inhibiting Multiple Proinflammatory Signaling Pathways and Restoring Intestinal Homeostasis. J Med Chem 2022. [PMID: 36053746 DOI: 10.1021/acs.jmedchem.2c00390] [Reference Citation Analysis]
10 Lee J, Chung K, Shin J, Jung S, Lee S, Lee M, Hong H, Rhee YK, Lee K. Anti-Colitic Effect of an Exopolysaccharide Fraction from Pediococcus pentosaceus KFT-18 on Dextran Sulfate Sodium-Induced Colitis through Suppression of Inflammatory Mediators. Polymers 2022;14:3594. [DOI: 10.3390/polym14173594] [Reference Citation Analysis]
11 He C, Chen Z, Huang J, Gan R, Wang J, Wang L, Li D, Yao J, Hussain T. Interleukin-22 Ameliorates Dextran Sulfate Sodium-Induced Colitis through the Upregulation of lncRNA-UCL to Accelerate Claudin-1 Expression via Sequestering miR-568 in Mice. Oxidative Medicine and Cellular Longevity 2022;2022:1-18. [DOI: 10.1155/2022/8543720] [Reference Citation Analysis]
12 Song Y, Yuan M, Xu Y, Xu H. Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing. Pharmaceuticals 2022;15:1080. [DOI: 10.3390/ph15091080] [Reference Citation Analysis]
13 Yan G, Wang X, Fan Y, Lin J, Yan J, Wang L, Pan D, Xu Y, Yang M. Immuno-PET Imaging of TNF-α in Colitis Using 89Zr-DFO-infliximab. Mol Pharm 2022. [PMID: 36039398 DOI: 10.1021/acs.molpharmaceut.2c00411] [Reference Citation Analysis]
14 Su Y, Tao T, Liu X, Su W. JAK-STAT Signaling Pathway in Non-Infectious Uveitis. Biochem Pharmacol 2022;:115236. [PMID: 36041544 DOI: 10.1016/j.bcp.2022.115236] [Reference Citation Analysis]
15 Liu W, Chen X, Li H, Zhang J, An J, Liu X. Anti-Inflammatory Function of Plant-Derived Bioactive Peptides: A Review. Foods 2022;11:2361. [PMID: 35954128 DOI: 10.3390/foods11152361] [Reference Citation Analysis]
16 Tsiogka A, Kyriazopoulou M, Kontochristopoulos G, Nicolaidou E, Stratigos A, Rigopoulos D, Gregoriou S. The JAK/STAT Pathway and Its Selective Inhibition in the Treatment of Atopic Dermatitis: A Systematic Review. JCM 2022;11:4431. [DOI: 10.3390/jcm11154431] [Reference Citation Analysis]
17 Adolph TE, Meyer M, Schwärzler J, Mayr L, Grabherr F, Tilg H. The metabolic nature of inflammatory bowel diseases. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35906289 DOI: 10.1038/s41575-022-00658-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Zhu Y, Shen R, Vuong I, Reynolds RA, Shears MJ, Yao ZC, Hu Y, Cho WJ, Kong J, Reddy SK, Murphy SC, Mao HQ. Multi-step screening of DNA/lipid nanoparticles and co-delivery with siRNA to enhance and prolong gene expression. Nat Commun 2022;13:4282. [PMID: 35879315 DOI: 10.1038/s41467-022-31993-y] [Reference Citation Analysis]
19 Mishra S, Jena A, Kakadiya R, Sharma V, Ahuja V. Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2022.2106216] [Reference Citation Analysis]
20 Hong Z, Xie J, Wang X, Dai J, Mao J, Bai Y, Sheng J, Tian Y. Moringa oleifera Lam. Peptide Remodels Intestinal Mucosal Barrier by Inhibiting JAK-STAT Activation and Modulating Gut Microbiota in Colitis. Front Immunol 2022;13:924178. [DOI: 10.3389/fimmu.2022.924178] [Reference Citation Analysis]
21 Aoyama K, Itokawa N, Oshima M, Iwama A. Epigenetic Memories in Hematopoietic Stem and Progenitor Cells. Cells 2022;11:2187. [DOI: 10.3390/cells11142187] [Reference Citation Analysis]
22 Verstockt B, Volk V, Jaeckel C, Alsoud D, Sabino J, Nikolaus S, Outtier A, Krönke N, Feuerhake F, De Hertogh G, Rosenstiel P, Vermeire S, Schreiber S, Ferrante M, Aden K. Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis. Aliment Pharmacol Ther 2022;56:282-91. [PMID: 35484689 DOI: 10.1111/apt.16955] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Zhao Y, Bai L, Zhang Y, Yao R, Sun Y, Hang R, Chen X, Wang H, Yao X, Xiao Y, Hang R. Type I collagen decorated nanoporous network on titanium implant surface promotes osseointegration through mediating immunomodulation, angiogenesis, and osteogenesis. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121684] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Luo T, Wang Y, Tang H, Zhou F, Chen Y, Pei B, Wang J. An AAV-Based NF-κB-Targeting Gene Therapy (rAAV-DMP-miR533) to Inflammatory Diseases. J Inflamm Res 2022;15:3447-66. [PMID: 35726215 DOI: 10.2147/JIR.S362732] [Reference Citation Analysis]
25 Ma S, Zhang J, Liu H, Li S, Wang Q. The Role of Tissue-Resident Macrophages in the Development and Treatment of Inflammatory Bowel Disease. Front Cell Dev Biol 2022;10:896591. [PMID: 35721513 DOI: 10.3389/fcell.2022.896591] [Reference Citation Analysis]
26 Xu Y, Huang Y, Zhang S, Guo L, Wu R, Fang X, Chen X, Xu H, Nie Q. CircDCLRE1C Regulated Lipopolysaccharide-Induced Inflammatory Response and Apoptosis by Regulating miR-214b-3p/STAT3 Pathway in Macrophages. Int J Mol Sci 2022;23:6822. [PMID: 35743265 DOI: 10.3390/ijms23126822] [Reference Citation Analysis]
27 Coquant G, Aguanno D, Brot L, Belloir C, Delugeard J, Roger N, Pham H, Briand L, Moreau M, de Sordi L, Carrière V, Grill J, Thenet S, Seksik P. 3-oxo-C12:2-HSL, quorum sensing molecule from human intestinal microbiota, inhibits pro-inflammatory pathways in immune cells via bitter taste receptors. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-13451-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Napolitano M, D'amico F, Ragaini E, Peyrin-biroulet L, Danese S. Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy. DDDT 2022;Volume 16:1897-913. [DOI: 10.2147/dddt.s340459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Hone Lopez S, Jalving M, Fehrmann RS, Nagengast WB, de Vries EG, de Haan JJ. The gut wall’s potential as a partner for precision oncology in immune checkpoint treatment. Cancer Treatment Reviews 2022;107:102406. [DOI: 10.1016/j.ctrv.2022.102406] [Reference Citation Analysis]
30 Yusuf K, Saha S, Umar S. Health Benefits of Dietary Fiber for the Management of Inflammatory Bowel Disease. Biomedicines 2022;10:1242. [DOI: 10.3390/biomedicines10061242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Fang H. PiER: web-based facilities tailored for genetic target prioritisation harnessing human disease genetics, functional genomics and protein interactions. Nucleic Acids Res 2022:gkac379. [PMID: 35610036 DOI: 10.1093/nar/gkac379] [Reference Citation Analysis]
32 Li X, Wang M, Liu C, Xiao Y, Li M, Ban C, Huang Y, Cheng M, Song L, Liu G, Lu S, Wang C, Ren Z. Qingfeiyin Decoction Inhibits H1N1 Virus Infection via Modulation of Gut Microbiota and Inflammatory Pathways in a Murine Model. Front Pharmacol 2022;13:874068. [DOI: 10.3389/fphar.2022.874068] [Reference Citation Analysis]
33 Cao Q, Mertens RT, Sivanathan KN, Cai X, Xiao P. Macrophage orchestration of epithelial and stromal cell homeostasis in the intestine. J Leukoc Biol 2022. [PMID: 35593111 DOI: 10.1002/JLB.3RU0322-176R] [Reference Citation Analysis]
34 Kumar B, Field NS, Kim DD, Dar AA, Chen Y, Suresh A, Pastore CF, Hung LY, Porter N, Sawada K, Shah P, Elbulok O, Moser EK, Herbert DR, Oliver PM. The ubiquitin ligase Cul5 regulates CD4+ T cell fate choice and allergic inflammation. Nat Commun 2022;13:2786. [PMID: 35589717 DOI: 10.1038/s41467-022-30437-x] [Reference Citation Analysis]
35 Itokawa N, Oshima M, Koide S, Takayama N, Kuribayashi W, Nakajima-takagi Y, Aoyama K, Yamazaki S, Yamaguchi K, Furukawa Y, Eto K, Iwama A. Epigenetic traits inscribed in chromatin accessibility in aged hematopoietic stem cells. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-30440-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 De Kleijn KMA, Straasheijm KR, Zuure WA, Martens GJM. Molecular Signature of Neuroinflammation Induced in Cytokine-Stimulated Human Cortical Spheroids. Biomedicines 2022;10:1025. [DOI: 10.3390/biomedicines10051025] [Reference Citation Analysis]
37 Hanzel J, Hulshoff MS, Grootjans J, D'Haens G. Emerging therapies for ulcerative colitis. Expert Rev Clin Immunol 2022. [PMID: 35477319 DOI: 10.1080/1744666X.2022.2069562] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Serigado JM, Foulke-abel J, Hines WC, Hanson JA, In J, Kovbasnjuk O. Ulcerative Colitis: Novel Epithelial Insights Provided by Single Cell RNA Sequencing. Front Med 2022;9:868508. [DOI: 10.3389/fmed.2022.868508] [Reference Citation Analysis]
39 Villablanca EJ, Selin K, Hedin CRH. Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression? Nat Rev Gastroenterol Hepatol 2022. [PMID: 35440774 DOI: 10.1038/s41575-022-00604-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
40 Hartwig O, Loretz B, Nougarede A, Jary D, Sulpice E, Gidrol X, Navarro F, Lehr CM. Leaky gut model of the human intestinal mucosa for testing siRNA-based nanomedicine targeting JAK1. J Control Release 2022:S0168-3659(22)00163-8. [PMID: 35339579 DOI: 10.1016/j.jconrel.2022.03.037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
41 Ma L, Yu J, Zhang H, Zhao B, Zhang J, Yang D, Luo F, Wang B, Jin B, Liu J. Effects of Immune Cells on Intestinal Stem Cells: Prospects for Therapeutic Targets. Stem Cell Rev and Rep. [DOI: 10.1007/s12015-022-10347-7] [Reference Citation Analysis]
42 Zhao J, Zhang B, Mao Q, Ping K, Zhang P, Lin F, Liu D, Feng Y, Sun M, Zhang Y, Li QH, Zhang T, Mou Y, Wang S. Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5-ASA-PABA-MAC and 5-ASA-PABA-Diamine for the Treatment of Ulcerative Colitis. J Med Chem 2022. [PMID: 35275619 DOI: 10.1021/acs.jmedchem.1c02166] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Li Y, Yao C, Xiong Q, Xie F, Luo L, Li T, Feng P. Network meta‐analysis on efficacy and safety of different Janus kinase inhibitors for ulcerative colitis. Clinical Pharmacy Therapeu. [DOI: 10.1111/jcpt.13622] [Reference Citation Analysis]
44 Aghamohammad S, Sepehr A, Miri ST, Najafi S, Rohani M, Pourshafiea MR. The effects of the probiotic cocktail on modulation of the NF-kB and JAK/STAT signaling pathways involved in the inflammatory response in bowel disease model. BMC Immunol 2022;23:8. [PMID: 35240996 DOI: 10.1186/s12865-022-00484-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Cording S, Lhermitte L, Malamut G, Berrabah S, Trinquand A, Guegan N, Villarese P, Kaltenbach S, Meresse B, Khater S, Dussiot M, Bras M, Cheminant M, Tesson B, Bole-Feysot C, Bruneau J, Molina TJ, Sibon D, Macintyre E, Hermine O, Cellier C, Asnafi V, Cerf-Bensussan N; CELAC network. Oncogenetic landscape of lymphomagenesis in coeliac disease. Gut 2022;71:497-508. [PMID: 33579790 DOI: 10.1136/gutjnl-2020-322935] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
46 Baba AB, Rah B, Bhat GR, Mushtaq I, Parveen S, Hassan R, Hameed Zargar M, Afroze D. Transforming Growth Factor-Beta (TGF-β) Signaling in Cancer-A Betrayal Within. Front Pharmacol 2022;13:791272. [DOI: 10.3389/fphar.2022.791272] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
47 Bochicchio MT, Di Battista V, Poggio P, Carrà G, Morotti A, Brancaccio M, Lucchesi A. Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms. Cancers (Basel) 2022;14:972. [PMID: 35205715 DOI: 10.3390/cancers14040972] [Reference Citation Analysis]
48 Xu P, Guan H, Xiao W, Sun L. The role of IL-36 subfamily in intestinal disease. Biochem Soc Trans 2022:BST20211264. [PMID: 35166319 DOI: 10.1042/BST20211264] [Reference Citation Analysis]
49 Grossberg LB, Papamichael K, Cheifetz AS. Review: emerging drug therapies in inflammatory bowel disease. Aliment Pharmacol Ther 2022. [PMID: 35166398 DOI: 10.1111/apt.16785] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
50 Valdés-lópez JF, Fernandez GJ, Urcuqui-inchima S. Synergistic Effects of Toll-Like Receptor 1/2 and Toll-Like Receptor 3 Signaling Triggering Interleukin 27 Gene Expression in Chikungunya Virus-Infected Macrophages. Front Cell Dev Biol 2022;10:812110. [DOI: 10.3389/fcell.2022.812110] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 El-Ghannam MS, Saad MA, Nassar NN, El-Yamany MF, El-Bahy AAZ. Linagliptin ameliorates acetic acid-induced colitis via modulating AMPK/SIRT1/PGC-1α and JAK2/STAT3 signaling pathway in rats. Toxicol Appl Pharmacol 2022;:115906. [PMID: 35122774 DOI: 10.1016/j.taap.2022.115906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
52 Wang X, Xie L, Long J, Liu K, Lu J, Liang Y, Cao Y, Dai X, Li X. Therapeutic effect of baicalin on inflammatory bowel disease: A review. J Ethnopharmacol 2022;283:114749. [PMID: 34666140 DOI: 10.1016/j.jep.2021.114749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
53 Tamarit-sebastian S, Ferrer-soler FM, Lucendo AJ. Current options and investigational drugs for the treatment of eosinophilic esophagitis. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2033207] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 La Manna S, De Benedictis I, Marasco D. Proteomimetics of Natural Regulators of JAK-STAT Pathway: Novel Therapeutic Perspectives. Front Mol Biosci 2021;8:792546. [PMID: 35047557 DOI: 10.3389/fmolb.2021.792546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Lintzeri DA, Constantinou A, Hillmann K, Ghoreschi K, Vogt A, Blume-Peytavi U. Alopecia areata - Aktuelles Verständnis und Management. J Dtsch Dermatol Ges 2022;20:59-93. [PMID: 35040563 DOI: 10.1111/ddg.14689_g] [Reference Citation Analysis]
56 Lintzeri DA, Constantinou A, Hillmann K, Ghoreschi K, Vogt A, Blume-Peytavi U. Alopecia areata - Current understanding and management. J Dtsch Dermatol Ges 2022;20:59-90. [PMID: 35040577 DOI: 10.1111/ddg.14689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Wu Y, Song H. A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease. Life 2022;12:130. [DOI: 10.3390/life12010130] [Reference Citation Analysis]
58 Massimino L, Spanò S, Lamparelli LA, Fuggetta D, Peyrin-Biroulet L, Sileri P, Danese S, D'Alessio S, Ungaro F. Tofacitinib Inhibits Leukocyte Trafficking Across the Intestinal Endothelial Barrier in a Specific Cohort of Ulcerative Colitis Patients. Inflamm Bowel Dis 2022:izab349. [PMID: 35032171 DOI: 10.1093/ibd/izab349] [Reference Citation Analysis]
59 Ito K, Matsuda Y, Mine A, Shikida N, Takahashi K, Miyairi K, Shimbo K, Kikuchi Y, Konishi A. Single-chain tandem macrocyclic peptides as a scaffold for growth factor and cytokine mimetics. Commun Biol 2022;5:56. [PMID: 35031676 DOI: 10.1038/s42003-022-03015-6] [Reference Citation Analysis]
60 Bassotti G, Fruganti A, Maconi G, Marconi P, Fettucciari K. Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease May be Favoured by the Effects of Proinflammatory Cytokines on the Enteroglial Network. J Inflamm Res 2021;14:7443-53. [PMID: 35002278 DOI: 10.2147/JIR.S328628] [Reference Citation Analysis]
61 Tanaka Y, Luo Y, O'Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol 2022. [PMID: 34987201 DOI: 10.1038/s41584-021-00726-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 27.0] [Reference Citation Analysis]
62 Veisman I, Ben-Horin S. Editorial: tofacitinib post-marketing safety reports among ulcerative colitis patients. Aliment Pharmacol Ther 2022;55:131-2. [PMID: 34907564 DOI: 10.1111/apt.16681] [Reference Citation Analysis]
63 Arnauts K, Sudhakar P, Verstockt S, Lapierre C, Potche S, Caenepeel C, Verstockt B, Raes J, Vermeire S, Sabino J, Verfaillie C, Ferrante M. Microbiota, not host origin drives ex vivo intestinal epithelial responses. Gut Microbes 2022;14:2089003. [PMID: 35758256 DOI: 10.1080/19490976.2022.2089003] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
64 Liu D, Ge H, Xu F, Xu Y, Liu W, Li H, Zhu L, Diao Y, Zhao Z. Design, synthesis and SAR study of 2-aminopyridine derivatives as potent and selective JAK2 inhibitors. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2021.12.099] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Parigi TL, Solitano V, Peyrin-Biroulet L, Danese S. Do JAK inhibitors have a realistic future in treating Crohn's disease? Expert Rev Clin Immunol 2021;:1-3. [PMID: 34971341 DOI: 10.1080/1744666X.2022.2020101] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Cheng WX, Ren Y, Lu MM, Xu LL, Gao JG, Chen D, Kalyani FS, Lv ZY, Chen CX, Ji F, Lin HN, Jin X. Palmitoylation in Crohn’s disease: Current status and future directions. World J Gastroenterol 2021; 27(48): 8201-8215 [DOI: 10.3748/wjg.v27.i48.8201] [Reference Citation Analysis]
67 Zhang H, Zhao B, Wei H, Zeng H, Sheng D, Zhang Y. Cucurbitacin B controls M2 macrophage polarization to suppresses metastasis via targeting JAK-2/STAT3 signalling pathway in colorectal cancer. J Ethnopharmacol 2021;287:114915. [PMID: 34954267 DOI: 10.1016/j.jep.2021.114915] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
68 Perri MR, Romano C, Marrelli M, Zicarelli L, Toma CC, Basta D, Conforti F, Statti G. Beneficial Role of Fruits, Their Juices, and Freeze-Dried Powders on Inflammatory Bowel Disease and Related Dysbiosis. Plants (Basel) 2021;11:4. [PMID: 35009009 DOI: 10.3390/plants11010004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
69 Lashgari NA, Momeni Roudsari N, Khayatan D, Shayan M, Momtaz S, Roufogalis BD, Abdolghaffari AH, Sahebkar A. Ginger and its constituents: Role in treatment of inflammatory bowel disease. Biofactors 2021. [PMID: 34882874 DOI: 10.1002/biof.1808] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
70 Meneghini M, Bestard O, Grinyo JM. Immunosuppressive drugs modes of action. Best Pract Res Clin Gastroenterol 2021;54-55:101757. [PMID: 34874841 DOI: 10.1016/j.bpg.2021.101757] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
71 Zhou Y, Hu Z, Ye F, Guo T, Luo Y, Zhou W, Qin D, Tang Y, Cao F, Luo F, Lin Q. Mogroside V exerts anti-inflammatory effect via MAPK-NF-κB/AP-1 and AMPK-PI3K/Akt/mTOR pathways in ulcerative colitis. Journal of Functional Foods 2021;87:104807. [DOI: 10.1016/j.jff.2021.104807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Akiyama S, Lin A, Traboulsi C, Rubin DT. Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib. ACG Case Rep J 2021;8:e00690. [PMID: 34840997 DOI: 10.14309/crj.0000000000000690] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Dudek P, Fabisiak A, Zatorski H, Malecka-Wojciesko E, Talar-Wojnarowska R. Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment. J Clin Med 2021;10:5660. [PMID: 34884361 DOI: 10.3390/jcm10235660] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
74 Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther 2021;6:402. [PMID: 34824210 DOI: 10.1038/s41392-021-00791-1] [Cited by in F6Publishing: 55] [Reference Citation Analysis]
75 Awasthi N, Liongue C, Ward AC. STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer. J Hematol Oncol 2021;14:198. [PMID: 34809691 DOI: 10.1186/s13045-021-01214-y] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
76 D'Amico F, Magro F, Peyrin-Biroulet L, Danese S. Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis. J Crohns Colitis 2021:jjab206. [PMID: 34791103 DOI: 10.1093/ecco-jcc/jjab206] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
77 Li Y, Chen J, Bolinger AA, Chen H, Liu Z, Cong Y, Brasier AR, Pinchuk IV, Tian B, Zhou J. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021;27:S38-62. [PMID: 34791293 DOI: 10.1093/ibd/izab190] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
78 Nayar S, Cho JH. From single-target to cellular niche targeting in Crohn's disease: intercepting bad communications. EBioMedicine 2021;74:103690. [PMID: 34773892 DOI: 10.1016/j.ebiom.2021.103690] [Reference Citation Analysis]
79 Loh JT, Lee KG, Lee AP, Teo JKH, Lim HL, Kim SS, Tan AH, Lam KP. DOK3 maintains intestinal homeostasis by suppressing JAK2/STAT3 signaling and S100a8/9 production in neutrophils. Cell Death Dis 2021;12:1054. [PMID: 34743196 DOI: 10.1038/s41419-021-04357-5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
80 Atreya R, Neurath MF. Deciphering Novel Mechanistic and Pharmacokinetic Effects of Tofacitinib in Intestinal Inflammation: Expect the Unexpected. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00217-4. [PMID: 34740616 DOI: 10.1016/j.jcmgh.2021.10.003] [Reference Citation Analysis]
81 Si X, Liu N, Jia H, Wang J, Pan L, Dong L, Rong Z, Yang Y, Wu Z. Gut relief formula attenuates dextran sulfate sodium-induced colitis by regulating NF-κB signaling and the intestinal microbiota in mice. Food Funct 2021;12:10983-93. [PMID: 34652352 DOI: 10.1039/d1fo01477c] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
82 Boldyreva LV, Morozova MV, Saydakova SS, Kozhevnikova EN. Fat of the Gut: Epithelial Phospholipids in Inflammatory Bowel Diseases. Int J Mol Sci 2021;22:11682. [PMID: 34769112 DOI: 10.3390/ijms222111682] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
83 Ding P, Liu J, Li Q, Lu Q, Li J, Shi R, Shi L, Mao T, Ge D, Niu H, Peng G, Wang Z. Investigation of the Active Ingredients and Mechanism of Hudi Enteric-Coated Capsules in DSS-Induced Ulcerative Colitis Mice Based on Network Pharmacology and Experimental Verification. Drug Des Devel Ther 2021;15:4259-73. [PMID: 34675488 DOI: 10.2147/DDDT.S326029] [Reference Citation Analysis]
84 Rincon-Arevalo H, Aue A, Ritter J, Szelinski F, Khadzhynov D, Zickler D, Stefanski L, Lino AC, Körper S, Eckardt KU, Schrezenmeier H, Dörner T, Schrezenmeier EV. Altered increase in STAT1 expression and phosphorylation in severe COVID-19. Eur J Immunol 2021. [PMID: 34676541 DOI: 10.1002/eji.202149575] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
85 Canton M, Sánchez-Rodríguez R, Spera I, Venegas FC, Favia M, Viola A, Castegna A. Reactive Oxygen Species in Macrophages: Sources and Targets. Front Immunol 2021;12:734229. [PMID: 34659222 DOI: 10.3389/fimmu.2021.734229] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
86 Matucci A, Vivarelli E, Nencini F, Maggi E, Vultaggio A. Strategies Targeting Type 2 Inflammation: From Monoclonal Antibodies to JAK-Inhibitors. Biomedicines 2021;9:1497. [PMID: 34680614 DOI: 10.3390/biomedicines9101497] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
87 Yao M, Li L, Huang M, Tan Y, Shang Y, Meng X, Pang Y, Xu H, Zhao X, Lei W, Chang Y, Wang Y, Zhang D, Zhang B, Li Y. Sanye Tablet Ameliorates Insulin Resistance and Dysregulated Lipid Metabolism in High-Fat Diet-Induced Obese Mice. Front Pharmacol 2021;12:713750. [PMID: 34658856 DOI: 10.3389/fphar.2021.713750] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
88 Schumertl T, Lokau J, Rose-John S, Garbers C. Function and proteolytic generation of the soluble interleukin-6 receptor in health and disease. Biochim Biophys Acta Mol Cell Res 2021;1869:119143. [PMID: 34626681 DOI: 10.1016/j.bbamcr.2021.119143] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
89 Wang L, Feng Y, Wang J, Luo T, Wang X, Wu M, Wang R, Chen D, Li J, Wang J. Arbutin Ameliorates Murine Colitis by Inhibiting JAK2 Signaling Pathway. Front Pharmacol 2021;12:683818. [PMID: 34594215 DOI: 10.3389/fphar.2021.683818] [Reference Citation Analysis]
90 Cao Y, Rewatkar P, Wang R, Hasnain SZ, Popat A, Kumeria T. Nanocarriers for oral delivery of biologics: small carriers for big payloads. Trends Pharmacol Sci 2021;42:957-72. [PMID: 34593258 DOI: 10.1016/j.tips.2021.08.005] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
91 Tian L, Zhao JL, Kang JQ, Guo SB, Zhang N, Shang L, Zhang YL, Zhang J, Jiang X, Lin Y. Astragaloside IV Alleviates the Experimental DSS-Induced Colitis by Remodeling Macrophage Polarization Through STAT Signaling. Front Immunol 2021;12:740565. [PMID: 34589089 DOI: 10.3389/fimmu.2021.740565] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
92 Chang X, March M, Mentch F, Nguyen K, Glessner J, Qu H, Liu Y, Furuta G, Aceves S, Gonsalves N, Nadeau K, Cianferoni A, Spergel J, Sleiman P, Hakonarson H. A genome-wide association meta-analysis identifies new eosinophilic esophagitis loci. J Allergy Clin Immunol 2021:S0091-6749(21)01358-0. [PMID: 34506852 DOI: 10.1016/j.jaci.2021.08.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
93 Woznicki JA, Saini N, Flood P, Rajaram S, Lee CM, Stamou P, Skowyra A, Bustamante-Garrido M, Regazzoni K, Crawford N, McDade SS, Longley DB, Aza-Blanc P, Shanahan F, Zulquernain SA, McCarthy J, Melgar S, McRae BL, Nally K. TNF-α synergises with IFN-γ to induce caspase-8-JAK1/2-STAT1-dependent death of intestinal epithelial cells. Cell Death Dis 2021;12:864. [PMID: 34556638 DOI: 10.1038/s41419-021-04151-3] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
94 Stankovic B, Kotur N, Nikcevic G, Gasic V, Zukic B, Pavlovic S. Machine Learning Modeling from Omics Data as Prospective Tool for Improvement of Inflammatory Bowel Disease Diagnosis and Clinical Classifications. Genes (Basel) 2021;12:1438. [PMID: 34573420 DOI: 10.3390/genes12091438] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
95 Shan W, Zhang W, Xue F, Ma Y, Dong L, Wang T, Zheng Y, Feng D, Chang M, Yuan G, Wang X. Schistosoma japonicum peptide SJMHE1 inhibits acute and chronic colitis induced by dextran sulfate sodium in mice. Parasit Vectors 2021;14:455. [PMID: 34488863 DOI: 10.1186/s13071-021-04977-y] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
96 Moser B, Edtmayer S, Witalisz-Siepracka A, Stoiber D. The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia. Biomedicines 2021;9:1051. [PMID: 34440253 DOI: 10.3390/biomedicines9081051] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
97 Hasriadi, Dasuni Wasana PW, Vajragupta O, Rojsitthisak P, Towiwat P. Mechanistic Insight into the Effects of Curcumin on Neuroinflammation-Driven Chronic Pain. Pharmaceuticals (Basel) 2021;14:777. [PMID: 34451874 DOI: 10.3390/ph14080777] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
98 Kwon YJ, Seo EB, Kim SK, Noh KH, Lee H, Joung YW, Shin HM, Jang YA, Kim YM, Lee JT, Ye SK. Chamaecyparis obtusa (Siebold & Zucc.) Endl. leaf extracts prevent inflammatory responses via inhibition of the JAK/STAT axis in RAW264.7 cells. J Ethnopharmacol 2021;:114493. [PMID: 34364971 DOI: 10.1016/j.jep.2021.114493] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
99 Veloso PM, Machado R, Nobre C. Mesalazine and inflammatory bowel disease - From well-established therapies to progress beyond the state of the art. Eur J Pharm Biopharm 2021;167:89-103. [PMID: 34329709 DOI: 10.1016/j.ejpb.2021.07.014] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
100 Rudra S, Shaul E, Conrad M, Patel T, Moore A, Dawany N, Canavan MC, Sullivan KE, Behrens E, Kelsen JR. Ruxolitinib: Targeted Approach for Treatment of Autoinflammatory Very Early Onset Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00822-3. [PMID: 34329777 DOI: 10.1016/j.cgh.2021.07.040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
101 Mühlenbeck H, Bender KW, Zipfel C. Importance of tyrosine phosphorylation for transmembrane signaling in plants. Biochem J 2021;478:2759-74. [PMID: 34297043 DOI: 10.1042/BCJ20210202] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
102 Valdés-López JF, Fernandez GJ, Urcuqui-Inchima S. Interleukin 27 as an inducer of antiviral response against chikungunya virus infection in human macrophages. Cell Immunol 2021;367:104411. [PMID: 34325085 DOI: 10.1016/j.cellimm.2021.104411] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
103 Song F, Zhang Y, Pan Z, Hu X, Zhang Q, Huang F, Ye X, Huang P. The role of alcohol dehydrogenase 1C in regulating inflammatory responses in ulcerative colitis. Biochem Pharmacol 2021;192:114691. [PMID: 34293286 DOI: 10.1016/j.bcp.2021.114691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Duan L, Cheng S, Li L, Liu Y, Wang D, Liu G. Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease. Front Pharmacol 2021;12:684486. [PMID: 34335253 DOI: 10.3389/fphar.2021.684486] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
105 Lefevre PLC, Vande Casteele N. Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease. J Crohns Colitis 2020;14:S725-36. [PMID: 32160283 DOI: 10.1093/ecco-jcc/jjaa014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
106 Garrido-Trigo A, Salas A. Molecular Structure and Function of Janus Kinases: Implications for the Development of Inhibitors. J Crohns Colitis 2020;14:S713-24. [PMID: 32083640 DOI: 10.1093/ecco-jcc/jjz206] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
107 Roohani S, Tacke F. Liver Injury and the Macrophage Issue: Molecular and Mechanistic Facts and Their Clinical Relevance. Int J Mol Sci 2021;22:7249. [PMID: 34298870 DOI: 10.3390/ijms22147249] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
108 Chengxiao Y, Dongmei W, Kai Z, Hou L, Xiao H, Ding T, Liu D, Ye X, Linhardt RJ, Chen S. Challenges of pectic polysaccharides as a prebiotic from the perspective of fermentation characteristics and anti-colitis activity. Carbohydr Polym 2021;270:118377. [PMID: 34364621 DOI: 10.1016/j.carbpol.2021.118377] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
109 Danese S, Peyrin-Biroulet L. Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise. Inflamm Bowel Dis 2021:izab135. [PMID: 34089259 DOI: 10.1093/ibd/izab135] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
110 Aguilar D, Revilla L, Garrido-Trigo A, Panés J, Lozano JJ, Planell N, Esteller M, Lacerda AP, Guay H, Butler J, Davis JW, Salas A. Randomized Controlled Trial Substudy of Cell-specific Mechanisms of Janus Kinase 1 Inhibition With Upadacitinib in the Crohn's Disease Intestinal Mucosa: Analysis From the CELEST Study. Inflamm Bowel Dis 2021:izab116. [PMID: 34042156 DOI: 10.1093/ibd/izab116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
111 Nailwal NP, Doshi GM. Role of intracellular signaling pathways and their inhibitors in the treatment of inflammation. Inflammopharmacology 2021;29:617-40. [PMID: 34002330 DOI: 10.1007/s10787-021-00813-y] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
112 Moon SY, Kim KD, Yoo J, Lee JH, Hwangbo C. Phytochemicals Targeting JAK-STAT Pathways in Inflammatory Bowel Disease: Insights from Animal Models. Molecules 2021;26:2824. [PMID: 34068714 DOI: 10.3390/molecules26092824] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
113 Zhao J, Li R, Li Y, Chen J, Feng F, Sun C. Broadly Antiviral Activities of TAP1 through Activating the TBK1-IRF3-Mediated Type I Interferon Production. Int J Mol Sci 2021;22:4668. [PMID: 33925089 DOI: 10.3390/ijms22094668] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
114 Chen L, He M, Zhang M, Sun Q, Zeng S, Zhao H, Yang H, Liu M, Ren S, Meng X, Xu H. The Role of non-coding RNAs in colorectal cancer, with a focus on its autophagy. Pharmacol Ther 2021;226:107868. [PMID: 33901505 DOI: 10.1016/j.pharmthera.2021.107868] [Cited by in Crossref: 3] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
115 Xiang C, Liu M, Lu Q, Fan C, Lu H, Feng C, Yang X, Li H, Tang W. Blockade of TLRs-triggered macrophage activation by caffeic acid exerted protective effects on experimental ulcerative colitis. Cell Immunol 2021;365:104364. [PMID: 33932876 DOI: 10.1016/j.cellimm.2021.104364] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
116 Al-Bawardy B, Shivashankar R, Proctor DD. Novel and Emerging Therapies for Inflammatory Bowel Disease. Front Pharmacol 2021;12:651415. [PMID: 33935763 DOI: 10.3389/fphar.2021.651415] [Cited by in Crossref: 6] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
117 Reddig A, Voss L, Guttek K, Roggenbuck D, Feist E, Reinhold D. Impact of Different JAK Inhibitors and Methotrexate on Lymphocyte Proliferation and DNA Damage. J Clin Med 2021;10:1431. [PMID: 33916057 DOI: 10.3390/jcm10071431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
118 Chen M, Xiao L, Dai G, Lu P, Zhang Y, Li Y, Ni M, Rui Y. Inhibition of JAK-STAT Signaling Pathway Alleviates Age-Related Phenotypes in Tendon Stem/Progenitor Cells. Front Cell Dev Biol 2021;9:650250. [PMID: 33855026 DOI: 10.3389/fcell.2021.650250] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
119 Ali FEM, M Elfiky M, Fadda WA, Ali HS, Mahmoud AR, Mohammedsaleh ZM, Abd-Elhamid TH. Regulation of IL-6/STAT-3/Wnt axis by nifuroxazide dampens colon ulcer in acetic acid-induced ulcerative colitis model: Novel mechanistic insight. Life Sci 2021;276:119433. [PMID: 33794250 DOI: 10.1016/j.lfs.2021.119433] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
120 Du Y, Rong L, Cong Y, Shen L, Zhang N, Wang B. Macrophage polarization: an effective approach to targeted therapy of inflammatory bowel disease. Expert Opin Ther Targets 2021;25:191-209. [PMID: 33682588 DOI: 10.1080/14728222.2021.1901079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
121 Restellini S, Afif W. Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease. J Clin Med 2021;10:1242. [PMID: 33802816 DOI: 10.3390/jcm10061242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
122 Nakkala JR, Li Z, Ahmad W, Wang K, Gao C. Immunomodulatory biomaterials and their application in therapies for chronic inflammation-related diseases. Acta Biomater 2021;123:1-30. [PMID: 33484912 DOI: 10.1016/j.actbio.2021.01.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
123 Kargbo RB. Degradation of Janus Kinase for Potential Application in Immune Response Therapeutics. ACS Med Chem Lett 2021;12:316-7. [PMID: 33738050 DOI: 10.1021/acsmedchemlett.1c00058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
124 Jiang Y, Jarr K, Layton C, Gardner CD, Ashouri JF, Abreu MT, Sinha SR. Therapeutic Implications of Diet in Inflammatory Bowel Disease and Related Immune-Mediated Inflammatory Diseases. Nutrients 2021;13:890. [PMID: 33801883 DOI: 10.3390/nu13030890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
125 Stolzer I, Ruder B, Neurath MF, Günther C. Interferons at the crossroad of cell death pathways during gastrointestinal inflammation and infection. Int J Med Microbiol 2021;311:151491. [PMID: 33662871 DOI: 10.1016/j.ijmm.2021.151491] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
126 Zhang C, Qi W, Li Y, Tang M, Yang T, Liu K, Chen Y, Deng D, Xiang M, Chen L. Discovery of 3-(4-(2-((1H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease. J Med Chem 2021;64:1966-88. [PMID: 33593051 DOI: 10.1021/acs.jmedchem.0c01468] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
127 Xu P, Elizalde M, Masclee A, Pierik M, Jonkers D. Corticosteroid enhances epithelial barrier function in intestinal organoids derived from patients with Crohn's disease. J Mol Med (Berl) 2021;99:805-15. [PMID: 33575854 DOI: 10.1007/s00109-021-02045-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
128 Xu L, Zhang J, Wang Y, Zhang Z, Wang F, Tang X. Uncovering the mechanism of Ge-Gen-Qin-Lian decoction for treating ulcerative colitis based on network pharmacology and molecular docking verification. Biosci Rep 2021;41:BSR20203565. [PMID: 33409535 DOI: 10.1042/BSR20203565] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
129 Li J, Li Y, Zhou X, Wei L, Zhang J, Zhu S, Zhang H, Gao X, Sharifu LM, Wang S, Xi L, Feng L. Upregulation of IL-15 in the placenta alters trophoblasts behavior contributing to gestational diabetes mellitus. Cell Biosci 2021;11:33. [PMID: 33557944 DOI: 10.1186/s13578-021-00533-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
130 Devlin JC, Axelrad J, Hine AM, Chang S, Sarkar S, Lin JD, Ruggles KV, Hudesman D, Cadwell K, Loke P. Single-Cell Transcriptional Survey of Ileal-Anal Pouch Immune Cells From Ulcerative Colitis Patients. Gastroenterology 2021;160:1679-93. [PMID: 33359089 DOI: 10.1053/j.gastro.2020.12.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
131 Zhong YB, Kang ZP, Zhou BG, Wang HY, Long J, Zhou W, Zhao HM, Liu DY. Curcumin Regulated the Homeostasis of Memory T Cell and Ameliorated Dextran Sulfate Sodium-Induced Experimental Colitis. Front Pharmacol 2020;11:630244. [PMID: 33597887 DOI: 10.3389/fphar.2020.630244] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
132 Gonneaud A, Turgeon N, Boisvert FM, Boudreau F, Asselin C. JAK-STAT Pathway Inhibition Partially Restores Intestinal Homeostasis in Hdac1- and Hdac2-Intestinal Epithelial Cell-Deficient Mice. Cells 2021;10:224. [PMID: 33498747 DOI: 10.3390/cells10020224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
133 Surbek M, Tse W, Moriggl R, Han X. A centric view of JAK/STAT5 in intestinal homeostasis, infection, and inflammation. Cytokine 2021;139:155392. [PMID: 33482575 DOI: 10.1016/j.cyto.2020.155392] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
134 Favoino E, Prete M, Catacchio G, Ruscitti P, Navarini L, Giacomelli R, Perosa F. Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart? Autoimmun Rev 2021;20:102750. [PMID: 33482338 DOI: 10.1016/j.autrev.2021.102750] [Cited by in Crossref: 7] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
135 Alim K, Bruyère A, Lescoat A, Jouan E, Lecureur V, Le Vée M, Fardel O. Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity. Expert Opin Drug Metab Toxicol 2021;17:259-71. [PMID: 33292029 DOI: 10.1080/17425255.2021.1862084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
136 Aydemir MN, Aydemir HB, Korkmaz EM, Budak M, Cekin N, Pinarbasi E. Computationally predicted SARS-COV-2 encoded microRNAs target NFKB, JAK/STAT and TGFB signaling pathways. Gene Rep 2021;22:101012. [PMID: 33398248 DOI: 10.1016/j.genrep.2020.101012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
137 Nadpara N, Reichenbach ZW, Ehrlich AC, Friedenberg F. Current Status of Medical Therapy for Inflammatory Bowel Disease: The Wealth of Medications. Dig Dis Sci 2020;65:2769-79. [PMID: 32661765 DOI: 10.1007/s10620-020-06471-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
138 Peng S, Shen L, Tian MX, Li HM, Wang SS. Poly(ADP-ribose) polymerase-1 inhibitor ameliorates dextran sulfate sodium-induced colitis in mice by regulating the balance of Th17/Treg cells and inhibiting the NF-κB signaling pathway. Exp Ther Med 2021;21:134. [PMID: 33376516 DOI: 10.3892/etm.2020.9566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
139 Hernandez-rocha C, Vande Casteele N. JAK inhibitors: current position in treatment strategies for use in inflammatory bowel disease. Current Opinion in Pharmacology 2020;55:99-109. [DOI: 10.1016/j.coph.2020.10.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
140 Jezernik G, Mičetić-Turk D, Potočnik U. Molecular Genetic Architecture of Monogenic Pediatric IBD Differs from Complex Pediatric and Adult IBD. J Pers Med 2020;10:E243. [PMID: 33255894 DOI: 10.3390/jpm10040243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
141 Peterson DM, King BA. Gut instinct: Using tofacitinib to treat alopecia areata in the context of comorbid inflammatory bowel disease. JAAD Case Rep 2021;7:44-6. [PMID: 33319003 DOI: 10.1016/j.jdcr.2020.10.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
142 Alhouayek M, Ameraoui H, Muccioli GG. Bioactive lipids in inflammatory bowel diseases - From pathophysiological alterations to therapeutic opportunities. Biochim Biophys Acta Mol Cell Biol Lipids 2021;1866:158854. [PMID: 33157277 DOI: 10.1016/j.bbalip.2020.158854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
143 Damsky W, Peterson D, Ramseier J, Al-Bawardy B, Chun H, Proctor D, Strand V, Flavell RA, King B. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. J Allergy Clin Immunol 2021;147:814-26. [PMID: 33129886 DOI: 10.1016/j.jaci.2020.10.022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
144 Yu T, Li Z, Xu L, Yang M, Zhou X. Anti-inflammation effect of Qingchang suppository in ulcerative colitis through JAK2/STAT3 signaling pathway in vitro and in vivo. J Ethnopharmacol 2021;266:113442. [PMID: 33027643 DOI: 10.1016/j.jep.2020.113442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
145 Verstockt B, Van Hemelen M, Outtier A, Sabino J, Van Wijngaerden E, De Munter P, Ferrante M, Wilmer A, Vermeire S. Invasive nocardiosis, disseminated varicella zoster reactivation, and pneumocystis jiroveci pneumonia associated with tofacitinib and concomitant systemic corticosteroid use in ulcerative colitis. Journal of Gastroenterology and Hepatology 2020;35:2294-7. [DOI: 10.1111/jgh.15256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
146 Porter AC, Aubrecht J, Birch C, Braun J, Cuff C, Dasgupta S, Gale JD, Hinton R, Hoffmann SC, Honig G, Linggi B, Schito M, Casteele NV, Sauer JM. Biomarkers of Crohn's Disease to Support the Development of New Therapeutic Interventions. Inflamm Bowel Dis 2020;26:1498-508. [PMID: 32840322 DOI: 10.1093/ibd/izaa215] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
147 Qi J, Zhang Z, Tang X, Li W, Chen W, Yao G. IL-27 Regulated CD4+IL-10+ T Cells in Experimental Sjögren Syndrome. Front Immunol 2020;11:1699. [PMID: 32849596 DOI: 10.3389/fimmu.2020.01699] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
148 Jadhav P, Jiang Y, Jarr K, Layton C, Ashouri JF, Sinha SR. Efficacy of Dietary Supplements in Inflammatory Bowel Disease and Related Autoimmune Diseases. Nutrients 2020;12:E2156. [PMID: 32698454 DOI: 10.3390/nu12072156] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
149 Biemans VB, Verstockt B. Tofacitinib, two-faced Janus in ulcerative colitis and Crohn's disease? United European Gastroenterol J 2020;8:753-4. [PMID: 32640933 DOI: 10.1177/2050640620942641] [Reference Citation Analysis]
150 Zhao X, Zhang E, Ren X, Bai X, Wang D, Bai L, Luo D, Guo Z, Wang Q, Yang J. Edaravone alleviates cell apoptosis and mitochondrial injury in ischemia-reperfusion-induced kidney injury via the JAK/STAT pathway. Biol Res 2020;53:28. [PMID: 32620154 DOI: 10.1186/s40659-020-00297-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
151 Magro F, Estevinho MM. Is tofacitinib a game-changing drug for ulcerative colitis? United European Gastroenterol J 2020;8:755-63. [PMID: 32552501 DOI: 10.1177/2050640620935732] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
152 Nasonov EL, Avdeeva AS, Lila AM. EFFICACY AND SAFETY OF TOFACITINIB FOR IMMUNEMEDIATED INFLAMMATORY RHEUMATIC DISEASES (PART II). Naučno-praktičeskaâ revmatologiâ 2020;58:214-24. [DOI: 10.14412/1995-4484-2020-214-224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]